New pill shows promise for diabetes control in Real-World study

NCT ID NCT05316662

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in Mexico. Researchers tracked changes in blood sugar and body weight over 8-10 months. The goal was to see if this pill helps lower blood sugar levels in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Rybelsus)
What this could lead to: If successful, this could confirm that oral semaglutide helps control blood sugar and weight in real-world settings, supporting its use for type 2 diabetes management.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also specific to Mexico, so findings may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC

Guadalajara, Jalisco, 44670, Mexico
Centro de Investigacion Clinica Endocrinologica de Jalisco

Guadalajara, Jalisco, 44670, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.